# South America Diabetic Retinopathy Market > South America Diabetic Retinopathy Market Research Report By Type (Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR)), By Treatment (Pharmacological Therapies, Laser Treatment, Surgery), By End-user (Hospitals & Clinics, Ophthalmology Centers, Research Institutes), and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.72% - **2024:** $ 407 Million - **2025:** $ 434.35 Million - **2035:** $ 832.5 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) **Report ID:** MRFR/HC/48710-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-diabetic-retinopathy-market-50467 --- ## Market Summary ## **South America Diabetic Retinopathy Market Overview** As per MRFR analysis, the South America Diabetic Retinopathy Market Size was estimated at 862 (USD Million) in 2023. The South America Diabetic Retinopathy Market is expected to grow from 905 (USD Million) in 2024 to 1,867 (USD Million) by 2035. The South America Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 6.805% during the forecast period (2025 - 2035). ### **Key South America Diabetic Retinopathy Market Trends Highlighted** The growing incidence of diabetes in the region is fuelling the market for diabetic retinopathy in South America. Diabetes retinopathy screening and treatment are in high demand as the number of diabetes patients continues to climb due to urbanization and lifestyle changes that result in greater obesity rates. Furthermore, government campaigns to increase public knowledge of diabetes-related eye conditions are essential for encouraging early detection and care. Increasing access to medical facilities for diabetic retinopathy screening has been the subject of programs run by health ministries in a number of South American nations. There are several opportunities in this industry as new ways to provide treatment to remote places are made possible by technological breakthroughs like telemedicine and AI-based screening tools. These developments have the potential to greatly improve early detection and treatment in many South American nations, where access to healthcare may be restricted. As a result of this growing technology integration, diabetic retinopathy is being managed more proactively, particularly in underprivileged populations. In order to create integrated care pathways, recent trends also show a greater emphasis on cooperation between government organisations, technological companies, and healthcare providers. These collaborations promote resource allocation and information exchange that can better meet the requirements of diabetic retinopathy patients. Increased patient education and awareness is also a result of community-based health programs that support early intervention by empowering people to take control of their eye health. Thus, these advancements point to a bright and forward-looking future for the South American diabetic retinopathy market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South America Diabetic Retinopathy Market Drivers** ### **Increasing Incidence of Diabetes in South America** The prevalence of diabetes in South America has been on a steady rise, with estimates suggesting that around 32 million adults in the region are currently living with diabetes, according to the International Diabetes Federation. This growing patient population directly correlates to an increased risk of complications, including diabetic retinopathy, which affects about one-third of all individuals with diabetes. This connection underscores the urgent need for improved diagnostic and treatment options within the South America Diabetic Retinopathy Market. Many health organizations and governmental bodies are prioritizing diabetes management programs, thus boosting the demand for effective retinal care solutions. Governments have even begun to implement more focused health policies to manage this epidemic, strengthening the growth potential of the South America Diabetic Retinopathy Market. ### **Advancements in Ophthalmic Technologies** The South America Diabetic Retinopathy Market is witnessing significant benefits from advancements in ophthalmic technologies, including enhanced imaging modalities such as Optical Coherence Tomography (OCT) and advanced retinal lasers for treatment. These technologies have improved efficiency in diagnosing and treating diabetic retinopathy, enabling earlier intervention and reduced progression rates of the disease. For instance, devices that can identify retinal changes at an earlier stage are critical in South America, where healthcare systems are increasingly integrating sophisticated technologies into routine care. The uptake of these technological advancements by major health institutions signifies a shift in treatment protocols, led by organizations like the Brazilian Society of Ophthalmology, further driving market growth. ### **Government Initiatives and Health Awareness Campaigns** Governments across South America are launching initiatives aimed at increasing awareness about diabetic complications, including diabetic retinopathy. For example, countries like Brazil and Argentina have implemented national health programs that focus on diabetes education and regular screening practices. These efforts are crucial, as they aim to reduce the long-term healthcare burden associated with untreated diabetic complications. Such improvements in public health initiatives are expected to increase patient accessibility to eye care services, thus driving the demand for treatments in the South America Diabetic Retinopathy Market. This proactive approach aligns with health strategies promoted by international health organizations, aiming to lower the incidence of diabetes-related complications across the region. ## **South America Diabetic Retinopathy Market Segment Insights** ### **Diabetic Retinopathy Market Type Insights** The South America Diabetic Retinopathy Market is influenced by its distinct segments, particularly Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). These two segments play critical roles in the overall landscape, reflecting different stages of the disease and their respective impacts on patient health. NPDR is typically recognized as the early stage of diabetic retinopathy, characterized by changes in the blood vessels of the eye, such as swelling and leakage. This segment holds significant importance as it accounts for a large proportion of diabetic retinopathy cases, providing a crucial opportunity for early intervention and management. In contrast, PDR represents a more advanced and severe form of the disease, indicating the growth of new blood vessels in the retina, which can lead to vision loss. This segment poses higher treatment complexity and often leads to more serious medical interventions, making it critical for healthcare systems in South America. With an increasingly aging population and rising incidences of diabetes, both NPDR and PDR are expected to see growing cases, thus stressing the need for effective screening and treatment programs across the region. Additionally, the healthcare community emphasizes the importance of screening for NPDR, as early detection can significantly alter disease progression and improve patient outcomes. The regional healthcare landscape benefits from ongoing advancements in treatment protocols which are crucial in managing these conditions effectively, highlighting the inherent opportunities within the South America Diabetic Retinopathy Market. Understanding the intricacies of these segments enables stakeholders to align their strategies with market demands and further enhance the quality of care in South American nations. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Diabetic Retinopathy Market Treatment Insights** The Treatment segment of the South America Diabetic Retinopathy Market plays a crucial role in managing this increasingly prevalent eye condition, which affects many residents in the region due to rising diabetes rates. Effective management strategies include various approaches, such as Pharmacological Therapies, which are vital for controlling inflammation and slow disease progression. Laser Treatment is another significant method, as it helps in reducing vision loss, thereby improving the quality of life for patients. Surgery, although less commonly employed, is essential for advanced cases, offering opportunities for restoration of vision. The treatment landscape in South America is supported by a growing population of diabetic patients, highlighting a need for continued advancements and accessibility in options. Overall, the Treatment segment not only addresses immediate health concerns but also emphasizes the importance of early intervention and regular eye examinations, contributing to a broader public health strategy aimed at combating diabetes-related complications across the region. The market growth is further propelled by increasing awareness and education initiatives regarding the importance of managing diabetic retinopathy effectively. ### **Diabetic Retinopathy Market End-user Insights** The South America Diabetic Retinopathy Market significantly revolves around its End-user segment, which plays a crucial role in providing essential care and treatment for patients affected by diabetic eye conditions. Hospitals and Clinics represent a dominant force within this segment, offering a range of diagnostic and therapeutic services, thus ensuring accessibility to healthcare for a vast number of patients. While Ophthalmology Centers focus specifically on eye care, specializing in advanced treatment procedures and often equipped with cutting-edge technology, Research Institutes contribute valuable insights into the disease through innovative research, facilitating the development of new treatment methodologies. The convergence of these institutions fosters collaboration, enhancing patient outcomes and addressing the rising prevalence of diabetic retinopathy in South America. With a growing diabetic population in the region, the demand for specialized care and comprehensive management of diabetic retinopathy is anticipated to increase, driving substantial growth within this segment. The market dynamics are influenced by the rising incidence of diabetes, an aging population, and increased awareness about eye health, making the End-user segment a pivotal component within the South America Diabetic Retinopathy Market landscape. Furthermore, the integration of telemedicine and digital health solutions by these End-users is opening new avenues for patient engagement and follow-up care, enhancing overall treatment efficacy. ### **Diabetic Retinopathy Market Regional Insights** The South America Diabetic Retinopathy Market exhibits a diverse and dynamic landscape, reflecting the varying healthcare demands across different nations. Brazil stands out as a significant player, given its large population and rising diabetes prevalence, signaling a robust need for effective diabetic retinopathy management solutions. Meanwhile, Mexico's healthcare initiatives are gaining traction, with increased government funding focused on eye care awareness and treatment accessibility, further boosting its market relevance. Argentina, characterized by its unique healthcare challenges and opportunities, showcases a growing commitment to eye health, indicating its potential within the industry. The Rest of South America segment contributes to a steadily expanding market, driven by increasing health awareness and improvements in healthcare infrastructure across several countries in the region. As diabetes rates rise across South America, the assigned priority for diabetic retinopathy treatment illustrates a noticeable growth trend within the South America Diabetic Retinopathy Market, fueled by advancements in technology and treatment methodologies. These segmentation insights reflect both current and potential future dynamics in the region, marking a path for strategic developments in diabetic retinopathy interventions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South America Diabetic Retinopathy Market Key Players and Competitive Insights** The South America Diabetic Retinopathy Market is characterized by a diverse array of companies competing to address a critical healthcare challenge stemming from rising diabetes prevalence in the region. As diabetic retinopathy can lead to severe vision impairment and is one of the major complications associated with diabetes, understanding the competitive landscape is essential for market players aiming to enhance their foothold. Key factors influencing competition include innovative treatment solutions, strategic collaborations, regulatory landscapes, and a growing focus on patient accessibility to care. The market is primarily driven by advancements in diagnostic technologies, therapeutic practices, and an increasing awareness of preventive measures among healthcare professionals and the patient population. Santen Pharmaceutical, operating within the South American Diabetic Retinopathy Market, has established a notable presence characterized by its commitment to developing ophthalmologic products and solutions that cater to patients suffering from eye diseases, including diabetic retinopathy. The company’s strength lies in its dedicated focus on research and development, which has enabled it to offer specialized therapies aimed at addressing vision complications associated with diabetes. Through various partnerships with local healthcare providers and stakeholders, Santen Pharmaceutical is effectively enhancing its visibility in the region while reinforcing its innovative product pipeline tailored for the needs of South American populations. Bayer has made significant inroads into the South America Diabetic Retinopathy Market with a solid portfolio of key products that target the management of retinal diseases. The company's strengths often stem from its extensive research-driven approach, which not only facilitates the introduction of advanced therapeutic options but also positions Bayer as a trusted brand among medical professionals and patients alike. The firm has pursued various mergers and acquisitions to bolster its capabilities in this market, enabling it to expand its product offerings and services, thereby enhancing its competitive edge. Through a network of local subsidiaries and healthcare partnerships, Bayer continues to engage in outreach and education initiatives targeting diabetic retinopathy, further solidifying its presence in South America and addressing the urgent need for effective treatment solutions in this area. ### **Key Companies in the South America Diabetic Retinopathy Market Include** ## **South America Diabetic Retinopathy Market Developments** Recent developments in the South America Diabetic Retinopathy Market reveal a growing focus on innovative treatments and technologies among key companies like Santen Pharmaceutical, Bayer, Novartis, and Regeneron. In October 2023, Bayer announced advancements in its Retinal Treatment Program aimed at enhancing efficacy in diabetic retinopathy management. The market is experiencing growth driven by increasing diabetes prevalence in countries like Brazil and Argentina, prompting healthcare providers to invest in better screening and treatment options. In terms of mergers and acquisitions, Novartis acquired a biotech firm specializing in retinal diseases in September 2023, enhancing its portfolio in this segment. Companies such as Roche and Valeant Pharmaceuticals are also collaborating with local research institutions to develop tailored solutions for South American populations, thereby boosting their market presence. Recent figures indicate that the South American market's valuation for diabetic retinopathy treatments is projected to reach significant milestones by 2025, influenced by the combined efforts of pharmaceutical companies and healthcare systems to address this growing health concern. Such developments underscore the urgency and importance of effective management strategies for diabetic retinopathy in the region. ## **South America Diabetic Retinopathy Market Segmentation Insights** ### **Diabetic Retinopathy Market Type Outlook** ### **Diabetic Retinopathy Market Treatment Outlook** ### **Diabetic Retinopathy Market End-user Outlook** ### **Diabetic Retinopathy Market Regional Outlook** ## Market Drivers ### Aging Population The demographic shift towards an aging population in South America will significantly impact the diabetic retinopathy market. As individuals age, the prevalence of diabetes and its complications, including diabetic retinopathy, tends to increase. By 2030, it is projected that the population aged 60 and above in South America will reach approximately 20% of the total population. This demographic trend suggests a growing patient base requiring specialized care for diabetic retinopathy. Consequently, healthcare providers may need to enhance their services and treatment modalities to cater to this aging demographic, thereby driving growth in the diabetic retinopathy market. ### Rising Healthcare Expenditure The increase in healthcare expenditure across South America is another significant driver for the diabetic retinopathy market. Governments and private sectors are investing more in healthcare infrastructure, which includes the provision of advanced diagnostic and treatment facilities for diabetic retinopathy. In recent years, healthcare spending in South America has seen a growth rate of approximately 5% annually, reflecting a commitment to improving health outcomes. This financial support enables the adoption of innovative technologies and therapies, enhancing the overall management of diabetic retinopathy. As healthcare systems evolve, the diabetic retinopathy market is likely to benefit from improved access to care and a wider range of treatment options. ### Advancements in Treatment Modalities The continuous advancements in treatment modalities for diabetic retinopathy are likely to propel the market forward. Innovative therapies, such as anti-VEGF injections and laser treatments, have shown promising results in managing the disease. In South America, the introduction of these advanced treatment options has the potential to improve patient outcomes significantly. The market for diabetic retinopathy is expected to grow as healthcare providers adopt these new technologies, which may lead to better management of the disease and reduced incidence of vision loss. The increasing availability of these treatments is indicative of a dynamic market landscape that is responsive to patient needs. ### Increasing Awareness of Diabetic Retinopathy The growing awareness regarding diabetic retinopathy among healthcare professionals and patients is a crucial driver for the diabetic retinopathy market in South America. Educational campaigns and initiatives by health organizations have led to improved understanding of the disease, its symptoms, and the importance of early detection. This heightened awareness is likely to result in increased screening and diagnostic procedures, thereby expanding the market. In South America, it is estimated that around 30% of individuals with diabetes may develop some form of diabetic retinopathy, underscoring the need for effective management strategies. As more patients become informed about the risks associated with diabetes, the demand for treatment options in the diabetic retinopathy market is expected to rise significantly. ### Rising Incidence of Diabetes-Related Complications The rising incidence of diabetes-related complications in South America serves as a critical driver for the diabetic retinopathy market. As the number of individuals diagnosed with diabetes continues to grow, the associated complications, including diabetic retinopathy, are becoming more prevalent. Reports indicate that nearly 50% of individuals with diabetes may develop some form of retinopathy over their lifetime. This alarming statistic highlights the urgent need for effective screening and treatment options. Consequently, healthcare systems are likely to prioritize the management of diabetic retinopathy, leading to increased investments in the market. The focus on addressing these complications is expected to foster growth and innovation within the diabetic retinopathy market. ## Future Outlook The [Diabetic Retinopathy Market](https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792) diabetic retinopathy market is projected to grow at a 6.72% CAGR from 2025 to 2035, driven by increasing diabetes prevalence, technological advancements, and enhanced healthcare access. **New opportunities:** - Development of telemedicine platforms for remote diagnosis and monitoring. Investment in AI-driven diagnostic tools to improve accuracy and efficiency. Expansion of patient education programs to enhance treatment adherence. By 2035, the market is expected to achieve substantial growth, driven by innovation and increased healthcare initiatives. ## Segment Insights ### By Type: Non-Proliferative Diabetic Retinopathy (Largest) vs. Proliferative Diabetic Retinopathy (Fastest-Growing) In the South America diabetic retinopathy market, Non-Proliferative Diabetic Retinopathy (NPDR) holds the largest share, primarily due to its higher prevalence among the populations affected by diabetes. The NPDR segment is characterized by its non-advanced stage, which allows for better prognosis and treatment options, thereby attracting more focus from healthcare providers. On the other hand, Proliferative Diabetic Retinopathy (PDR) is gaining traction as it represents the advanced stage of retinopathy, which can lead to severe vision loss if not addressed promptly, making it a critical focus area for both research and innovation. Growth trends indicate an increasing incidence of diabetes in South America, which directly correlates with a rise in diabetic retinopathy cases. The PDR segment is expected to grow faster due to the urgent need for effective treatment methods and advancements in medical technology. Drivers such as increased awareness about eye health and the critical need for early diagnosis are further propelling the growth of the segment, thereby leading to a promising outlook for both types in the market. NPDR (Dominant) vs. PDR (Emerging) Non-Proliferative Diabetic Retinopathy (NPDR) is characterized by the accumulation of retinal microaneurysms and retinal hemorrhages, making it the dominant segment in the South America diabetic retinopathy market. It represents the early stages of the disease and has a significant share due to the manageable nature of its progression. On the other hand, Proliferative Diabetic Retinopathy (PDR) is an emerging segment, signaling advanced eye disease that poses a risk of permanent vision loss. The growth in PDR is fueled by increasing diabetes complications and heightened awareness regarding the importance of early-stage detection. Together, these segments represent critical components in understanding the broader landscape of diabetic retinopathy. ### By Treatment: Pharmacological Therapies (Largest) vs. Laser Treatment (Fastest-Growing) In the treatment segment for diabetic retinopathy, Pharmacological Therapies hold the largest market share, dominating the landscape due to their widespread usage and established efficacy. Laser Treatment follows closely, recognized for its effectiveness in preventing vision loss, thus capturing a significant portion of the market. Surgery contributes a smaller fraction but remains relevant for advanced cases where other treatments fail. Growth trends are increasingly favoring Laser Treatment, which is rapidly gaining traction among healthcare providers and patients alike. Factors driving this shift include technological advancements and greater patient awareness about treatment options. The flexibility and effectiveness of pharmacological therapies also ensure their continued relevance, even as emerging treatments evolve to address the complexities of diabetic retinopathy more robustly. Pharmacological Therapies (Dominant) vs. Surgery (Emerging) Pharmacological Therapies remain the dominant approach in treating diabetic retinopathy, leveraging medications that slow the progression of the disease and preserve vision. This segment is characterized by a range of options, including anti-VEGF agents, which are widely endorsed by ophthalmologists due to their proven benefits. Conversely, Surgery stands as an emerging alternative, utilized when other treatments are inadequate. Although its market share is smaller, surgical methods like vitrectomy offer solutions for severe cases. This duality between dominant pharmacological options and emerging surgical techniques illustrates a comprehensive treatment landscape, accommodating various stages of diabetic retinopathy. ### By End User: Hospitals & Clinics (Largest) vs. Ophthalmology Centers (Fastest-Growing) In the South America diabetic retinopathy market, Hospitals & Clinics emerge as the largest segment, capturing a significant share of the total market. These facilities are often the first point of contact for patients, offering comprehensive eye care and treatment for diabetic retinopathy. On the other hand, Ophthalmology Centers, while currently smaller in market share, are experiencing rapid growth due to increased awareness and specialized services that cater specifically to eye diseases associated with diabetes. Their focused approach attracts more patients seeking dedicated care. Growth trends in this market segment are driven largely by the rising incidence of diabetes and subsequent eye complications. As healthcare access continues to improve in various South American countries, Hospitals & Clinics benefit from a broader patient base. Meanwhile, Ophthalmology Centers are characterized by their innovative treatment options and patient education programs, which are vital in managing diabetes-related eye conditions effectively. The expansion of these centers is further encouraged by advancements in medical technology and increased funding for specialized research. Hospitals & Clinics (Dominant) vs. Ophthalmology Centers (Emerging) Hospitals & Clinics play a dominant role in the diabetic retinopathy segment, providing essential services including early diagnosis, treatment, and ongoing management of eye diseases linked to diabetes. Their integrated approach to healthcare enables them to cater to a large volume of patients, making them a critical component of the healthcare infrastructure. Conversely, Ophthalmology Centers represent an emerging segment with a focus on specialized care, offering cutting-edge treatments and personalized patient experiences. These centers are equipped with advanced technology and trained specialists who provide comprehensive care tailored to diabetic retinopathy patients. Their ability to respond to specific patient needs contributes to their burgeoning growth, as they establish themselves as critical players in the management of diabetic eye diseases. ## Regional Market Share Analysis ### Brazil : Brazil's Expanding Diabetic Care Sector Key markets include São Paulo, Rio de Janeiro, and Brasília, where healthcare facilities are rapidly adopting advanced technologies. The competitive landscape features major players like Novartis, Roche, and Bayer, which have established a strong presence through partnerships and local manufacturing. The business environment is favorable, with increasing investments in healthcare infrastructure. The ophthalmic sector is witnessing growth, driven by rising awareness and the introduction of innovative therapies for diabetic retinopathy. ### Mexico : Mexico's Rising Healthcare Investments Key markets include Mexico City, Guadalajara, and Monterrey, where healthcare facilities are expanding their capabilities. The competitive landscape features players like Regeneron and Alcon, which are actively involved in local partnerships. The business environment is improving, with a focus on public-private collaborations to enhance healthcare delivery. The ophthalmic sector is gaining traction, with increasing awareness of diabetic retinopathy and the importance of early intervention. ### Argentina : Argentina's Focus on Diabetic Care Key markets include Buenos Aires, Córdoba, and Rosario, where healthcare facilities are increasingly adopting advanced technologies. The competitive landscape features major players like Pfizer and Santen, which are focusing on expanding their market presence. The business environment is characterized by a mix of public and private healthcare providers, with ongoing efforts to improve diabetes management. The ophthalmic sector is evolving, with a focus on education and awareness campaigns to promote early diagnosis and treatment. ### Rest of South America : Varied Growth Across South America Key markets include countries like Chile, Colombia, and Peru, each with distinct healthcare landscapes. The competitive landscape is fragmented, with local and international players like Horizon Therapeutics and Bayer vying for market share. The business environment is diverse, with varying levels of healthcare investment and infrastructure development. The ophthalmic sector is witnessing growth, driven by increasing awareness of diabetic retinopathy and the need for early intervention. ## Competitive Benchmarking The competitive dynamics in the diabetic retinopathy market blend innovation, strategic partnerships, and regional expansion. Key growth drivers include the increasing prevalence of diabetes and the rising awareness of diabetic retinopathy as a significant complication. Major players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Roche (CH) are actively shaping the landscape through their focused operational strategies. Novartis (CH) emphasizes innovation in drug development, particularly in gene therapies, while Regeneron Pharmaceuticals (US) leverages its strong pipeline of monoclonal antibodies. Roche (CH) is enhancing its diagnostic capabilities, which complements its therapeutic offerings, thereby creating a comprehensive approach to diabetic retinopathy management. Collectively, these strategies foster a competitive environment that prioritizes advanced treatment options and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain efficiency and reduce costs. This approach is particularly relevant in South America, where logistical challenges can impede market access. The market structure appears moderately fragmented, with several key players exerting influence while also allowing for the emergence of smaller, innovative firms. The collective actions of these major companies contribute to a dynamic competitive landscape, where agility and responsiveness to market needs are paramount. In October 2025, Novartis (CH) announced a strategic partnership with a local biotechnology firm to co-develop a novel treatment for diabetic retinopathy. This collaboration is significant as it not only enhances Novartis's research capabilities but also allows for localized insights into patient needs, potentially accelerating the development timeline. Such partnerships may prove crucial in navigating the complexities of the South American market, where understanding regional nuances is vital for success. In September 2025, Regeneron Pharmaceuticals (US) expanded its clinical trial program for its leading monoclonal antibody treatment, aiming to include diverse patient populations across South America. This move underscores the company's commitment to inclusivity in clinical research, which may enhance the efficacy and acceptance of its therapies in varied demographics. By broadening its clinical trials, Regeneron is likely positioning itself to capture a larger market share while addressing the specific needs of South American patients. In August 2025, Roche (CH) launched a new diagnostic tool specifically designed for early detection of diabetic retinopathy, which is expected to revolutionize screening practices in the region. This innovation not only aligns with Roche's strategy of integrating diagnostics with therapeutics but also addresses a critical gap in early intervention. The introduction of such tools may lead to improved patient outcomes and establish Roche as a leader in comprehensive diabetic care. As of November 2025, current trends in the diabetic retinopathy market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, innovative treatment modalities, and reliable supply chains. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in an increasingly complex market. ## Recent News & Developments Recent developments in the South America Diabetic Retinopathy Market reveal a growing focus on innovative treatments and technologies among key companies like Santen Pharmaceutical, Bayer, Novartis, and Regeneron. In October 2023, Bayer announced advancements in its Retinal Treatment Program aimed at enhancing efficacy in diabetic retinopathy management. The market is experiencing growth driven by increasing diabetes prevalence in countries like Brazil and Argentina, prompting healthcare providers to invest in better screening and treatment options. In terms of mergers and acquisitions, Novartis acquired a biotech firm specializing in retinal diseases in September 2023, enhancing its portfolio in this segment. Companies such as Roche and Valeant Pharmaceuticals are also collaborating with local research institutions to develop tailored solutions for South American populations, thereby boosting their market presence. Recent figures indicate that the South American market's valuation for diabetic retinopathy treatments is projected to reach significant milestones by 2025, influenced by the combined efforts of pharmaceutical companies and healthcare systems to address this growing health concern. Such developments underscore the urgency and importance of effective management strategies for diabetic retinopathy in the region. ## Report Scope | MARKET SIZE 2024 | 407.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 434.35(USD Million) | | MARKET SIZE 2035 | 832.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.72% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) | | Segments Covered | Type, Treatment, End User | | Key Market Opportunities | Advancements in telemedicine and AI-driven diagnostics enhance access to diabetic retinopathy care. | | Key Market Dynamics | Rising prevalence of diabetes in South America drives demand for diabetic retinopathy screening and treatment solutions. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the market valuation for diabetic retinopathy in South America in 2024?** A: The market valuation for diabetic retinopathy in South America was $407.0 Million in 2024. **Q: What is the projected market valuation for diabetic retinopathy by 2035?** A: The projected market valuation for diabetic retinopathy is $832.5 Million by 2035. **Q: What is the expected CAGR for the South America diabetic retinopathy market during the forecast period 2025 - 2035?** A: The expected CAGR for the South America diabetic retinopathy market during the forecast period 2025 - 2035 is 6.72%. **Q: Which companies are considered key players in the South America diabetic retinopathy market?** A: Key players in the market include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Alcon, Pfizer, Santen Pharmaceutical, and Horizon Therapeutics. **Q: What are the market segments for diabetic retinopathy in South America?** A: The market segments include Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR), pharmacological therapies, laser treatment, and surgery. **Q: What was the valuation for Non-Proliferative Diabetic Retinopathy in 2024?** A: The valuation for Non-Proliferative Diabetic Retinopathy (NPDR) was $245.0 Million in 2024. **Q: What is the projected valuation for Proliferative Diabetic Retinopathy by 2035?** A: The projected valuation for Proliferative Diabetic Retinopathy (PDR) is $321.5 Million by 2035. **Q: How much revenue did pharmacological therapies generate in 2024?** A: Pharmacological therapies generated $150.0 Million in revenue in 2024. **Q: What is the expected revenue for laser treatment by 2035?** A: The expected revenue for laser treatment is $250.0 Million by 2035. **Q: Which end users are involved in the diabetic retinopathy market?** A: End users include hospitals & clinics, ophthalmology centers, and research institutes. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-diabetic-retinopathy-market-50467*